Age-related macular degeneration: An immunologically driven disease

Current Opinion in Investigational Drugs

Volumn 10, Issue 5, 2009, Pages 434-442

  Nussenblatt, R B ^a   Iu, B ^a   Li, Z ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT FACTOR H; FIBRONECTIN; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGING; BLINDNESS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MACROPHAGE ACTIVATION; MOLECULAR RECOGNITION; PATHOGENESIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

AGING; ANIMALS; HUMANS; IMMUNE SYSTEM; MACULAR DEGENERATION;

EID: 67649386575     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Cook HL, Patel PJ, Tufail A: Age-related macular degeneration: Diagnosis and management. Br Med Bull (2008) 85(1):127-149.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol (2004) 122(4):564-572.
3. Klein R, Peto T, Bird A, Vannewkirk MR: The epidemiology of age-related macular degeneration. Am J Ophthalmol (2004) 137(3):486-495.
4. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR: The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol (1989) 107(6):847-852.
5. Klein R, Klein BE, Jensen SC, Meuer SM: The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology (1997) 104(1):7-21.
6. Klein R, Meuer SM, Moss SE, Klein BE: Detection of drusen and early signs of age-related maculopathy using a nonmydriatic camera and a standard fundus camera. Ophthalmology (1992) 99(11):1686-1692.
7. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology (1995) 102(2):205-210.
8. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR: Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina (1994) 14(2):130-142.
9. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS, Milton RC, Bressler SB, Klein R: A simplified severity scale for age-related macular degeneration: AREDS Report No 18. Arch Ophthalmol (2005) 123(11):1570-1574.
10. Mullins RF, Aptsiauri N, Hageman GS: Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis. Eye (2001) 15(Pt 3):390-395.
11. Nussenblatt RB, Ferris F 3rd: Age-related macular degeneration and the immune response: Implications for therapy. Am J Ophthalmol (2007) 144(4):618-626.
12. Penfold PL, Killingsworth MC, Sarks SH: Senile macular degeneration: The involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol (1985) 223(2):69-76.
13. Penfold PL, Provis JM, Billson FA: Age-related macular degeneration: Ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol (1987) 225(1):70-76.
14. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2009) 28(1):1-18.
15. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG, Perez VL: Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med (2008) 14(2):194- 198.
16. Ferguson TA, Apte RS: Angiogenesis in eye disease: Immunity gained or immunity lost? Semin Immunopathol (2008) 30(2):111-119.
17. DeWan A, Bracken MB, Hoh J: Two genetic pathways for age- related macular degeneration. Curr Opin Genet Dev (2007) 17(3):228- 233.
18. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB: Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet (2005) 77(3):389-407.
19. Penfold PL, Madigan MC, Gillies MC, Provis JM: Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res (2001) 20(3):385-414.
20. Anderson DH, Mullins RF, Hageman GS, Johnson LV: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 134(3):411-431.
21. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA: Autoantibodies to retinal astrocytes associated with age- related macular degeneration. Graefes Arch Clin Exp Ophthalmol (1990) 228(3):270-274.
22. Patel N, Ohbayashi M, Nugent AK, Ramchand K, Toda M, Chau KY, Bunce C, Webster A, Bird AC, Ono SJ, Chong V: Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology (2005) 115(3):422-430.
23. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA (2005) 102(20):7227-7232.
24. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA: Complement factor H polymorphism and age-related macular degeneration. Science (2005) 308(5720):421-424.
25. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB et al: Complement factor H polymorphism in age-related macular degeneration. Science (2005) 308(5720):385-389.
26. Tuo J, Ning B, Bojanowski CM, Lin ZN, Ross RJ, Reed GF, Shen D, Jiao X, Zhou M, Chew EY, Kadlubar FF et al: Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci USA (2006) 103(24):9256-9261.
27. Ferrara DC, Merriam JE, Freund KB, Spaide RF, Takahashi BS, Zhitomirsky I, Fine HF, Yannuzzi LA, Allikmets R: Analysis of major alleles associated with age-related macular degeneration in patients with multifocal choroiditis: Strong association with complement factor H. Arch Ophthalmol (2008) 126(11):1562-1566.
28. Carroll MC: The complement system in regulation of adaptive immunity. Nat Immunol (2004) 5(10):981-986.
29. Nitsch D, Douglas I, Smeeth L, Fletcher A: Age-related macular degeneration and complement activation-related diseases: A population-based case-control study. Ophthalmology (2008) 115(11):1904-1910.
30. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG et al: Systemic complement activation in age-related macular degeneration. PLoS ONE (2008) 3(7):e2593.
31. Hollyfield JG, Salomon RG, Crabb JW: Proteomic approaches to understanding age-related macular degeneration. Adv Exp Med Biol (2003) 533:83-89.
32. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG et al: Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA (2002) 99(23):14682-14687.
33. Hageman GS, Mullins RF: Molecular composition of drusen as related to substructural phenotype. Mol Vis (1999) 5:28.
34. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF: An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE- Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 20(6):705-732.
35. Mullins RF, Russell SR, Anderson DH, Hageman GS: Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis and dense deposit disease. FASEB J (2000) 14(7):835-846.
36. Ozaki S, Johnson LV, Mullins RF, Hageman GS, Anderson DH: The human retina and retinal pigment epithelium are abundant sources of vitronectin mRNA. Biochem Biophys Res Commun (1999) 258(3):524-529.
37. Ross RJ, Zhou M, Shen D, Fariss RN, Ding X, Bojanowski CM, Tuo J, Chan CC: Immunological protein expression profile in Ccl2/ Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. Exp Eye Res (2008) 86(4):675-683.
38. Zhou J, Jang YP, Kim SR, Sparrow JR: Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA (2006) 103(44):16182-16187.
39. Schmidt CQ, Herbert AP, Hocking HG, Uhrin D, Barlow PN: Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol (2008) 151(1):14-24.
40. Meri S, Pangburn MK: Discrimination between activators and nonactivators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA (1990) 87(10):3982-3986.
41. Kristensen T, Tack BF: Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci USA (1986) 83(11):3963-3967.
42. Richards A, Kavanagh D, Atkinson JP: Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol (2007) 96:141-177.
43. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV: Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci USA (2006) 103(46):17456- 17461.
44. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S: Regulation of complement activation by C-reactive protein: Targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol (1999) 163(7):3957-3962.
45. Herbert AP, Deakin JA, Schmidt CQ, Blaum BS, Egan C, Ferreira VP, Pangburn MK, Lyon M, Uhrin D, Barlow PN: Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J Biol Chem (2007) 282(26):18960- 18968.
46. 402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 178(6):3831- 3836.
47. Sjöberg AP, Trouw LA, Clark SJ, Sjölander J, Heineglrd D, Sim RB, Day AJ, Blom AM: The factor H variant associated with age- related macular degeneration (His-384) and the non-disease- associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem (2007) 282(15):10894-10900.
48. Yu J, Wiita P, Kawaguchi R, Honda J, Jorgensen A, Zhang K, Fischetti VA, Sun H: Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. Biochemistry (2007) 46(28):8451-8461.
49. Hakobyan S, Harris CL, Tortajada A, Goicochea de Jorge E, Garcia-Layana A, Fernéndez-Robredo P, Rodriguez de Cordoba S, Morgan BP: Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: Application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 49(5):1983-1990.
50. Clark SJ, Higman VA, Mulloy B, Perkins SJ, Lea SM, Sim RB, Day AJ: His-384 allotypic variant of factor H associated with age- related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem (2006) 281(34):24713- 24720.
51. Koto T, Nagai N, Mochimaru H, Kurihara T, Izumi-Nagai K, Satofuka S, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K et al: Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice. Invest Ophthalmol Vis Sci (2007) 48(9):4328-4334.
52. Cummings KL, Waggoner SN, Tacke R, Hahn YS: Role of complement in immune regulation and its exploitation by virus. Viral Immunol (2007) 20(4):505-524.
53. Fearon DT, Carter RH: The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity. Annu Rev Immunol (1995) 13:127-149.
54. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science (1996) 272(5258):50-53.
55. Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Götze O, Zwirner J: Activated human T lymphocytes express a functional C3a receptor. J Immunol (2000) 165(11):6599-6605.
56. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME: Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity (2008) 28(3):425-435.
57. Nataf S, Davoust N, Ames RS, Barnum SR: Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol (1999) 162(7):4018-4023.
58. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF: Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 8(4):373-378.
59. Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC: C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol (2005) 16(12):3572-3582.
60. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS: Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood (2008) 112(5):1759-1766.
61. Killingsworth MC, Sarks JP, Sarks SH: Macrophages related to Bruch's membrane in age-related macular degeneration. Eye (1990) 4( Pt 4):613-621.
62. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW: Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 44(8):3586-3592.
63. Cousins SW, Espinosa-Heidmann DG, Csaky KG: Monocyte activation in patients with age-related macular degeneration: A biomarker of risk for choroidal neovascularization? Arch Ophthalmol (2004) 122(7):1013-1018.
64. Caicedo A, Espinosa-Heidmann DG, Pina Y, Hernandez EP, Cousins SW: Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp Eye Res (2005) 81(1):38-47.
65. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, Rollins BJ, Ambati BK: An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med (2003) 9(11):1390-1397.
66. Apte RS, Richter J, Herndon J, Ferguson TA: Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med (2006) 3(8):e310.
67. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 5(12):953-964.
68. Gordon S: Macrophage heterogeneity and tissue lipids. J Clin Invest (2007) 117(1):89-93.
69. Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity (2005) 23(4):344-346.
70. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci (2008) 13:453-461.
71. Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol (2006) 177(10):7303-7311.
72. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH: Human IL-23-producing type 1 macrophages promote but IL-10- producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci USA (2004) 101(13):4560-4565.
73. Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19(1):71-82.
74. hi monocytes dominate hypercholesterolemia- associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 117(1):195-205.
75. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA et al: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 117(1):185-194.
76. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR: Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes (2007) 56(1):16-23.
77. Kelly J, Ali Khan A, Yin J, Ferguson TA, Apte RS: Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest (2007) 117(11):3421-3426.
78. Caspi RR, Roberge FG, Nussenblatt RB: Organ-resident, nonlymphoid cells suppress proliferation of autoimmune T-helper lymphocytes. Science (1987) 237(4818):1029-1032.
79. Percopo CM, Hooks JJ, Shinohara T, Caspi R, Detrick B: Cytokine- mediated activation of a neuronal retinal resident cell provokes antigen presentation. J Immunol (1990) 145(12):4101-4107.
80. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med (1999) 340(2):115-126.
81. Jara LJ, Medina G, Vera-Lastra O, Amigo MC: Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev (2006) 5(3):195-201.
82. Stein-Streilein J, Streilein JW: Anterior chamber associated immune deviation (ACAID): Regulation, biological relevance, and implications for therapy. Int Rev Immunol (2002) 21(2-3):123-152.
83. Penfold PL, Gyory JF, Hunyor AB, Billson FA: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol (1995) 23(4):293-298.
84. Markomichelakis NN, Theodossiadis PG, Sfikakis PP: Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol (2005) 139(3):537-540.
85. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP: Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol (2009) 147(5):825-830, 830e.1.
86. Nussenblatt RB, Coleman H, Jirawuthiworavong G, Davuluri G, Potapova N, Dahr SS, Ragheb JA, Levy-Clarke G: The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand (2007) 85(2):230-231.
87. Igic R: Kallikrein and kininases in ocular tissues. Exp Eye Res (1985) 41(1):117-120.
88. Ma JX, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J: Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res (1996) 63(1):19-26.
89. Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX: Kallikrein- binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia (2003) 46(5):689-698.
90. Nagai N, Oike Y, Izumi-Nagai K, Koto T, Satofuka S, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Ishida S: Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: Minimal role of bradykinin. Invest Ophthalmol Vis Sci (2007) 48(5):2321-2326.
91. Lu F, Adelman RA: Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol (2009) 247(2):171-177.